Showing results (111-120 of 151) with videos related to
Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2024
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 ExpressionAditya Bardia, Hope S Rugo, Sara M Tolaney, et al.The New England Journal of Medicine|October 30, 2024
Inavolisib-Based Therapy in <i>PIK3CA</i>-Mutated Advanced Breast CancerNicholas C Turner, Seock-Ah Im, Cristina Saura, et al.Frontiers in Oncology|February 28, 2022
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b StudySara M Tolaney, Muralidhar Beeram, J Thaddeus Beck, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1KCarolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.Nature Communications|April 14, 2025
MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancerJunlong Jack Chi, Ping Xie, Mary Hongying Cheng, et al.The New England Journal of Medicine|February 21, 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerAditya Bardia, Ingrid A Mayer, Linda T Vahdat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH TrialKevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2024
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Komal Jhaveri, Seock-Ah Im, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast CancerKomal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Ingrid A Mayer, Jennifer R Diamond, et al.Pageof 16